<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004410</url>
  </required_header>
  <id_info>
    <org_study_id>199/13299</org_study_id>
    <secondary_id>CHMC-C-95-9-9</secondary_id>
    <secondary_id>CHMC-C-CRC-473</secondary_id>
    <secondary_id>CHMC-C-FDR001277</secondary_id>
    <nct_id>NCT00004410</nct_id>
  </id_info>
  <brief_title>Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine whether infants treated with tauroursodeoxycholic acid (TUDCA) have&#xD;
      a lower peak direct bilirubin, ALT, AST, glutamyltranspeptidase levels and a reduced duration&#xD;
      of cholestasis compared to the nontreatment arm.&#xD;
&#xD;
      II. Determine the significance of lower birth weight and longer duration of total parenteral&#xD;
      nutrition (TPN) on increasing risk of TPN associated cholestasis and increasing benefit from&#xD;
      TUDCA therapy.&#xD;
&#xD;
      III. Determine whether TUDCA therapy leads to significant reduction in the appearance of&#xD;
      biliary tract sludge and/or stone formation in these infants.&#xD;
&#xD;
      IV. Determine whether TUDCA therapy leads to reduced urinary excretion of potentially&#xD;
      hepatotoxic bile acids as compared to the untreated arm matched for birth weight and duration&#xD;
      of TPN.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by birth weight.&#xD;
&#xD;
      Patients are randomized in pairs by birth weight to receive either a placebo in arm I or&#xD;
      tauroursodeoxycholic acid (TUDCA) in arm II. TUDCA is administered by mouth, nasogastric&#xD;
      tube, or gastrostomy tube twice daily. After 2 weeks of therapy, a bile sample is obtained&#xD;
      via a duodenal tube. An ultrasound examination of the liver and biliary tract is performed&#xD;
      after 2 weeks and every 3 weeks thereafter until discontinuation of therapy or until presence&#xD;
      of biliary tract sludge is noted on 2 consecutive examinations.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date>March 2002</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cholestasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tauroursodeoxycholic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Hospitalized infants who are anticipated to require total parenteral nutrition for&#xD;
             greater than 2 weeks and have: Major gastrointestinal anomalies (gastroschisis,&#xD;
             ruptured omphalocele) OR Resection (necrotizing enterocolitis, volvulus)&#xD;
&#xD;
          -  No evidence of biliary tract abnormalities&#xD;
&#xD;
          -  No evidence of other forms of cholestatic liver disease&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Renal: No life threatening renal disease&#xD;
&#xD;
          -  Cardiovascular: No life threatening cardiovascular disease&#xD;
&#xD;
          -  Other: No multiple congenital abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Heubi</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 1998</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>cholestasis</keyword>
  <keyword>gastrointestinal disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodoxicoltaurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

